DDrare: Database of Drug Development for Rare Diseases

Searched query = "Microscopic polyangiitis", "MPA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5009111000001105; Alemtuzumab; Avacopan; Azathioprine; BELIMUMAB; Belimumab; Belimumab 10 mg/kg; Benlysta; Benlysta 400 mg powder for concentrate for solution for infusion; Benlysta 400mg polvere per concentrato per soluzione per infusione; Blisibimod; CCX168; CELLCEPT; CYCLOPHOSPHAMIDE; CellCept (mycophenolate mofetil); Cellcept; Chimeric monoclonal antibody, IgG4 subtype; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; DELTACORTENE; ENDOXAN BAXTER; Endoxan; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); GALEN® tablet; Glucocorticoid (GC); Glucocorticoids; Glucocorticoids (GC); Glucocorticoids - Reduced Dose; Glucocorticoids - Standard Dose; Glucocorticoids [Reduced Dose]; Glucocorticoids [Standard Dose]; Human normal immunoglobulin; Hydroxychloroquine; IFX-1; Infliximab; Intravenous immunoglobulins (human immunoglobulins G); Intravenous methyl prednisolone; MabThera; MabThera®; MabThera® 100MG; MabThera® 500MG; Methotrexate; Methyl prednisolone; Methylprednisolone; Methylprednisolone (or other glucocorticoid); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; Mycophenolic acid; Naltrexone; Naltrexone Hydrochloride; Other: No Plasma Exchange; PREDNISONE; Pednisone; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; PredniSONE Tablets, USP; Prednisolone; Prednison acis® 20 mg; Prednison acis® 5 mg; Prednisone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Procedure: Plasma Exchange; Procedure: Plasma exchange; RITUXIMAB; RIXATHON 500mg; RO0452294/V01; RO0452294/V02; Remission induction therapy; Rituximab; Rituximab (Arm A); Rituximab (Arm B); Ro106-1443; Sendoxan; Tocilizumab; Vitamin D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000012072	2013/12/01	01/12/2013	A prospective, open label, single arm, historical control trial of tocilizumab with corticosteroids in patients with microscopic polyangiitis		Microscopic polyangiitis	Tocilizumab group	Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	20	Phase 3	Japan
2	NCT00647166 (ClinicalTrials.gov)	May 2008	26/3/2008	Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)	Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors	MPA;PAN or EGPA With FFS=0;At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids	Drug: corticosteroid and azathioprine;Drug: corticosteroid and placebo	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	Both	114	Phase 3	France
3	NCT00307658 (ClinicalTrials.gov)	March 2001	27/3/2006	Intravenous Immunoglobulin After Relapse in Vasculitis	Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial	ANCA + Vasculitides Relapsing Either Under Corticosteroid;and Immunosuppressant Therapies or After One Year;Post Treatment.	Drug: Intravenous immunoglobulins (human immunoglobulins G)	Assistance Publique - Hôpitaux de Paris	NULL	Terminated	18 Years	N/A	Both	40	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000012072

2013/12/01

01/12/2013

A prospective, open label, single arm, historical control trial of tocilizumab with corticosteroids in patients with microscopic polyangiitis

Microscopic polyangiitis

Tocilizumab group

Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Phase 3

Japan

NCT00647166
(ClinicalTrials.gov)

May 2008

26/3/2008

Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)

Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors

MPA;PAN or EGPA With FFS=0;At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids

Drug: corticosteroid and azathioprine;Drug: corticosteroid and placebo

Assistance Publique - Hôpitaux de Paris

NULL

Completed

18 Years

N/A

Both

114

Phase 3

France

NCT00307658
(ClinicalTrials.gov)

March 2001

27/3/2006

Intravenous Immunoglobulin After Relapse in Vasculitis

Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial

ANCA + Vasculitides Relapsing Either Under Corticosteroid;and Immunosuppressant Therapies or After One Year;Post Treatment.

Drug: Intravenous immunoglobulins (human immunoglobulins G)

Assistance Publique - Hôpitaux de Paris

NULL

Terminated

18 Years

N/A

Both

Phase 3

France